Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Betts, Keith A. [1 ]
Chen, Clara [2 ]
Zichlin, Miriam L. [1 ]
Brun, Alexander [2 ]
Signorovitch, James E. [1 ]
Makenbaeva, Dinara [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-137
引用
收藏
页码：S334 / S335
页数：2
相关论文
共 50 条
  • [31] Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.
    Dimopoulos, Meletios A.
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna
    [J]. BLOOD, 2009, 114 (22) : 1122 - 1122
  • [32] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    Laubach, J. P.
    Mahindra, A.
    Mitsiades, C. S.
    Schlossman, R. L.
    Munshi, N. C.
    Ghobrial, I. M.
    Carreau, N.
    Hideshima, T.
    Anderson, K. C.
    Richardson, P. G.
    [J]. LEUKEMIA, 2009, 23 (12) : 2222 - 2232
  • [33] Novel treatment approaches for patients with relapsed and refractory multiple myeloma
    Sinha R.
    Lonial S.
    [J]. Current Treatment Options in Oncology, 2006, 7 (3) : 246 - 257
  • [34] Treatment of relapsed and refractory multiple myeloma in the era of novel agents
    van de Donk, Niels W. C. J.
    Lokhorst, Henk M.
    Dimopoulos, Meletios
    Cavo, Michele
    Morgan, Gareth
    Einsele, Hermann
    Kropff, Martin
    Schey, Steve
    Avet-Loiseau, Herve
    Ludwig, Heinz
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    Johnsen, Hans E.
    Blade, Joan
    San-Miguel, Jesus F.
    Palumbo, Antonio
    [J]. CANCER TREATMENT REVIEWS, 2011, 37 (04) : 266 - 283
  • [35] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    J P Laubach
    A Mahindra
    C S Mitsiades
    R L Schlossman
    N C Munshi
    I M Ghobrial
    N Carreau
    T Hideshima
    K C Anderson
    P G Richardson
    [J]. Leukemia, 2009, 23 : 2222 - 2232
  • [36] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [37] Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma
    Yang, Hongbo
    Roy, Anuja
    Yang, Chelsey
    McDonald, Evangeline
    Krishna, Arun
    Kuriakose, Emil T.
    Globe, Denise
    Siegel, David
    Jagannath, Sundar
    [J]. BLOOD, 2015, 126 (23)
  • [38] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 147 - 148
  • [39] Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
    Fotiou, Despina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [40] Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
    Maiese, Eric
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345